Barclays Maintains Overweight on Axogen, Raises Price Target to $60
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
Barclays analyst Christopher Pasquale maintains Axogen (NASDAQ:AXGN) with a Overweight and raises the price target from $50 to $60.
Barclays analyst Christopher Pasquale maintains Axogen (NASDAQ:AXGN) with a Overweight and raises the price target from $50 to $60.